IP Library Granted Patent US 9,506,034
Granted Patent B2
US 9,506,034 · App. 14/700,608 · Granted Nov 29, 2016

Method of enriching for pancreatic endoderm cells

Inventors: Olivia Kelly (San Diego, CA); Anne Bang (San Diego, CA)
Assignee: ViaCyte, Inc.
C12N5/0676C12N5/0678G01N33/68C12N2501/50C12N2501/599C12N2506/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,506,034
App. No.
14/700,608
Granted
Nov 29, 2016
Kind
B2
Abstract

The present disclosure relates to compositions and methods comprising cell surface markers for hES-derived cells, in particular, endoderm lineage cells including pancreatic endoderm-type cells, derived from hES cells.

Claims (16)

1. A method of enriching for pancreatic endoderm cells comprising:

a) exposing an in vitro cell population comprising pancreatic endoderm cells to a ligand that binds CD142, CD55, CD57, or CD98; and

b) selecting cells in the in vitro cell population that express CD142 or CD57, or selecting cells in the in vitro cell population that do not express CD55 or CD98, thereby enriching for pancreatic endoderm cells.

2. The method of claim 1 , wherein the pancreatic endoderm cells are derived from in vitro cultured pluripotent cells.

3. The method of claim 1 , wherein the cells selected express CD142.

4. The method of claim 1 , wherein the cells selected express CD57.

5. The method of claim 1 , wherein the cells selected express CD55.

6. The method of claim 1 , wherein the cells selected express CD98.

7. The method of claim 1 , wherein the cells selected express CD142 but do not express CD55.

8. The method of claim 1 , wherein the cells selected express CD142 but do not express CD98.

9. The method of claim 1 , wherein greater than 50% of the pancreatic endoderm cells selected in step b) express CD142 and pancreatic and duodenal homeobox gene 1 (PDX1).

10. The method of claim 1 , wherein greater than 50% of the pancreatic endoderm cells selected in step b) express CD57 and PDX1.

11. The method of claim 1 , wherein the ligand comprises an antibody or binding fragment thereof.

12. The method of claim 1 , wherein the ligand comprises a detectable label.

13. The method of claim 1 , wherein the ligand comprises a magnetic particle.

14. The method of claim 1 , wherein the cells are selected by Fluorescence Activated Cell Sorting (FACS).

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 31, 2016
From: KELLY, OLIVIA; BANG, ANNE
To: VIACYTE, INC.
Reel/Frame 038166/0290 →
Continuity (3)
Continuation 13724556 · Dec 21, 2012
Continuation 12107020 · Apr 21, 2008
Related Publication 20150299662A1 · Oct 22, 2015